IONIS PHARMACEUTICALS INCIONS

時価総額

$129.6億

PER

RNA標的創薬と医薬品の研究開発を行うバイオ製薬の大手。アンチセンスオリゴヌクレオチド薬や臨床試験を通じた希少疾患向け治療薬を展開。2023年1月にロイヤルティを5億ドルで売却、2024年9月に11.5百万株を公募で売却し489.1百万ドルを調達。米国を基盤に欧州や日本で臨床開発と商業化を展開。

概要財務

サマリーテーブルに戻る

	2010年 12月31日	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Revenue from the sale of medicines commercially as well as licensing and royalty revenues from other medicines, including SPINRAZA..	-	-	-	-	-	-	-	-	255	352	365	342	303	309	293
Royalty revenues from the sale of SPINRAZA (nusinersen).	-	-	-	-	-	-	-	-	-	-	287	268	242	240	216
Royalty revenues from the sale of WAINUA (eplontersen).	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20
Revenue from the sale of other medicines commercially as well as licensing and royalty revenue from other medicines, including TEGSEDI and WAYLIVRA.	-	-	-	-	-	-	-	-	-	-	-	-	-	68	57
Revenue from research and development services.	-	-	-	-	-	-	-	-	-	-	-	-	284	479	412
Revenue from research and development services performed under a collaborative agreement.	-	-	-	-	-	-	-	-	-	-	-	-	207	353	333
Joint development revenue for WAINUA (eplontersen).	-	-	-	-	-	-	-	-	-	-	-	-	-	126	79
Revenue	-	-	-	-	-	-	-	-	600	1,123	729	810	587	788	705
Cost of sales	-	-	-	-	-	-	-	-	2	4	12	11	14	9	11
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects. Also includes charges for amortization and write-downs of capitalized patent costs, as well as legal fees for patent litigation and patent defense.	-	-	-	-	-	322	344	375	415	466	535	643	833	900	902
Selling, general and administrative	-	-	-	-	-	-	-	108	245	287	354	186	150	233	267
Total operating expenses	-	-	-	-	-	-	-	-	-	757	901	841	998	1,141	1,180
Loss from operations	-48	-71	-69	-52	-48	-76	-46	25	-61	366	-172	-30	-410	-354	-475
Investment income	3	2	2	2	3	4	5	8	30	52	31	10	25	89	107
Interest expense	13	17	21	19	22	37	39	45	45	49	45	9	8	13	17
Amount of interest expense using the effective interest rate method and amortization of issuance costs related to the sale of future royalties.	-	-	-	-	-	-	-	-	-	-	-	-	-	69	73
Loss on investments	-1	4	1	2	1	-	-	-	-	-	17	10	-7	-2	-3
Gain (loss) on sale of real estate assets	-	-	-	-	-	-	-	-	-	-	-	-	150	-0	-0
Other income (expense)	-	-	-	-	-	-	-	-	-0	-1	-0	-1	-7	14	1
Loss before income tax benefit (expense)	-	-85	-75	-67	-54	-88	-84	-	-	-	-	-29	-258	-334	-460
Total income tax expense (benefit)	0	0	-	-	-15	0	3	-6	-291	44	317	-1	12	32	-6
Net loss	-61	-85	-65	-61	-39	-88	-87	-6	274	303	-451	-29	-270	-366	-454
Basic net loss per share (in dollars per share)	-0.62	-0.85	-	-	-	-	-	0.08	2.09	2.12	-3.23	-0.2	-1.9	-2.56	-3.04
Diluted net loss per share (in dollars per share)	-0.62	-0.85	-	-	-	-	-	0.08	2.07	2.08	-3.23	-0.2	-1.9	-2.56	-3.04